Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
EAST RUTHERFORD, N.J., May 15, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the 2017 UBS Global Healthcare Conference on May 22, 2017 at 10:30 a.m. EDT in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura IR Associate Tel: +201 804 3037 Email: [email protected]
